A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Trial Profile

A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs Lisocabtagene-maraleucel (Primary)
  • Indications B cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms TRANSCEND-NHL-006
  • Sponsors Juno Therapeutics
  • Most Recent Events

    • 04 Apr 2018 Planned End Date changed from 2 Apr 2021 to 2 May 2021.
    • 04 Apr 2018 Planned primary completion date changed from 2 Apr 2021 to 2 May 2021.
    • 04 Apr 2018 Planned initiation date changed from 2 Apr 2018 to 2 May 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top